Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Climb Bio (CLYM) Research & Development (2020 - 2026)

Climb Bio filings provide 7 years of Research & Development readings, the most recent being $9.4 million for Q1 2026.

  • Quarterly Research & Development fell 45.91% to $9.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $38.8 million through Mar 2026, up 26.78% year-over-year, with the annual reading at $46.7 million for FY2025, 225.84% up from the prior year.
  • Research & Development hit $9.4 million in Q1 2026 for Climb Bio, down from $13.7 million in the prior quarter.
  • Across five years, Research & Development topped out at $17.3 million in Q1 2025 and bottomed at $1.0 million in Q2 2024.
  • Average Research & Development over 5 years is $6.6 million, with a median of $6.0 million recorded in 2024.
  • The largest annual shift saw Research & Development plummeted 80.93% in 2024 before it skyrocketed 1488.18% in 2025.
  • Climb Bio's Research & Development stood at $4.9 million in 2022, then tumbled by 36.53% to $3.1 million in 2023, then soared by 90.57% to $6.0 million in 2024, then surged by 130.54% to $13.7 million in 2025, then tumbled by 31.77% to $9.4 million in 2026.
  • Per Business Quant, the three most recent readings for CLYM's Research & Development are $9.4 million (Q1 2026), $13.7 million (Q4 2025), and $9.1 million (Q3 2025).